# Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function

> **NCT03962049** · PHASE1 · COMPLETED · sponsor: **ObsEva SA** · enrollment: 24 (actual)

## Conditions studied

- Hepatic Impairment
- Healthy Participants

## Interventions

- **DRUG:** Linzagolix

## Key facts

- **NCT ID:** NCT03962049
- **Lead sponsor:** ObsEva SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-15
- **Primary completion:** 2019-10-23
- **Final completion:** 2019-11-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03962049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03962049, "Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03962049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*